Researchers have been awarded funding to work with a global leader in the speciality chemicals industry to create cleaner and greener chemical processing methods for everyday products in a bid to help the government meet its carbon neutral targets.
The University of Warwick spin-out company, CryoLogyx, has received a further investment from Oxford Technology Management and private investors, alongside £300k from InnovateUK.
When biological material (cells, blood, tissues) is frozen, cryoprotectants are used to prevent the damage associated with the formation of ice during the freezing process. New polymeric cryoprotectants are emerging, alongside the established cryoprotectants, but how exactly they manage to control ice formation and growth is still largely unknown. This is especially true for PVA, a deceptively simple synthetic polymer that interacts with ice by means of mechanisms that have now been revealed at the atomistic level thanks to researchers from the University of Warwick.
Using a 185 metre beamline at the Diamond synchrotron, researchers could see how Osmium, a rare precious metal that could be used for cancer treatments, reacts in a single human lung cancer cell. This is a major step forward in discovering new anti-cancer drugs for researchers at the University of Warwick.
The University of Warwick spin-out company, CryoLogyx, has been awarded £300k from InnovateUK to develop innovate cryopreservation agents with applications in the diagnostic, medicines discovery and cell-based therapy markets.